Recent Advances in Management of Renal Cell Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 October 2024 | Viewed by 118
Special Issue Editors
Interests: kidney cancer; prostate cancer; bladder cancer; chemotherapy; immunotherapy; clinical trials
2. School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9EU, UK
Interests: robotic surgery; urologic oncology; robotic prostatectomy; bladder cancer surgery
Interests: prostate cancer; radiation therapy; pineal parenchymal tumors; metastatic prostate cancer; proton therapy; hypofractionated radiotherapy; SABR; brachytherapy
Special Issue Information
Dear Colleagues,
First-line treatments with advanced renal cell carcinoma (aRCC) include immune check-point inhibitors used as dual-type combinations (ipilimumab and nivolumab) or tyrosine kinase inhibitors (nivolumab with cabozantinib, pembrolizumab with axitinib or levantinib, and avelumab with axitinib). Significant progress has been made in treatment of aRCC, and newer combinations are being investigated. Other drugs that inhibit hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF) signaling have demonstrated survival advantage. Tyrosine kinase inhibitors and mTor inhibitors have also shown an ability to inhibit aRCC growth. Key questions to answer in aRCC management include how to combine and sequence different types of therapies, as well as how to integrate new approaches in aRCC management.
The aim of this Special Issue is to define molecular and cellular targets in treating aRCC, including (1) the genetic basis and/or epigenetic mechanism of RCC; (2) drug resistance; (3) newer imaging modalities in diagnosis; (4) rare types of RCC; (5) newer drugs in aRCC treatment; (6) and real-world studies in aRCC. This Special Issue welcomes both original research articles and reviews.
Dr. Anand Sharma
Prof. Dr. Nikhil Vasdev
Dr. Prantik Das
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- renal cell carcinoma
- different types of therapies
- molecular and cellular targets
- genetic basis
- epigenetic mechanism
- drug resistance
- imaging modalities
- new drugs
- real world studies
